
Investors & Media
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources
Stockholder Tools
News Releases
News Releases
August 10, 2023
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
August 1, 2023
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
July 19, 2023
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
June 27, 2023
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
June 22, 2023
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,
May 16, 2023
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
May 11, 2023
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
May 3, 2023
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
April 21, 2023
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
April 20, 2023
MeiraGTx to Participate in Upcoming Investor Conferences
Displaying 1 - 10 of 11
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources